// App-Quantinova.ai

1302 : Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Guopan Yu

Principal Investigators

  • Dan Xu

  • Qifa Liu

  • Jing Sun

  • Zhiping Fan

  • Qiang Wang

  • Xiaoli Liu

  • Qianli Jiang

Medical Centers

  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cyclin Dependent Kinase Inhibitor 2A

  • Immunoglobulin heavy-chain variable region gene

Drug/Treatment

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved